A new clinical trial at University of California, San Francisco will test whether two existing drugs can improve survival and recovery for people with acute respiratory distress syndrome, a life-threatening condition that makes it difficult to breathe, UCSF officials said.
The PANTHER trial, set to begin Thursday, will study whether treatments matched to patients’ different forms of the disorder can improve outcomes. The trial, funded by the U.S. Department of Defense, will run at 10 institutions in the United States, with more sites planned abroad, according to a statement from UCSF on Monday.
Acute respiratory distress syndrome, or ARDS, affects about 1 in 10 patients in intensive care units and often develops after pneumonia, a severe infection or traumatic injury. The condition causes inflammation and fluid to build up in the lungs, making it harder for oxygen to reach the bloodstream, researchers said.
Between 35% and 45% of patients with ARDS die. According to UCSF, current treatment mainly involves supportive care, including mechanical ventilation, which can save lives but may also worsen lung injury.
The study builds on research by UCSF professors Carolyn Calfee and Michael Matthay, who identified two biological forms of ARDS: hyperinflammatory, which involves higher levels of inflammation, and hypo-inflammatory, which involves less inflammation.
That distinction may help explain why some treatments appear to benefit certain patients but not others, Calfee said.
Trial will involve only 300 patients
Researchers plan to enroll 300 patients at the U.S. sites. A blood test will classify participants into one of the two forms of ARDS before they are randomly assigned to treatment groups, UCSF officials said.
About one-third of participants will receive usual care. The rest will receive usual care along with one of two drugs: simvastatin, a widely used cholesterol-lowering drug with anti-inflammatory effects, or baricitinib, a drug that targets specific inflammatory pathways and is approved to treat rheumatoid arthritis.
The trial will track survival and the number of days patients remain alive without major life-support treatments, such as mechanical ventilation or medication to maintain blood pressure, during the first 28 days.
Researchers will also examine how well patients recover, according to Matthay.
“Can a patient walk independently, are they able to return to work. Are they recovering their cognitive skills and do they have the muscle strength to perform everyday tasks,” he said.
Many people who survive ARDS experience lasting physical limitations and problems with thinking and memory, according to the National Heart, Lung, and Blood Institute.
